Lilly, Novo battle for dominance in India's growing obesity market
HYDERABAD, India: With generic rivals waiting in the wings, Eli Lilly and Novo Nordisk are intensifying efforts to lock in market share in India's rapidly expanding obesity drug market, turning pricing, promotion, and partnerships into key competitive weapons.
The two global drugmakers are racing to strengthen their positions before lower-cost copies begin arriving as early as